cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
← catalyst calendarNCT06686485 · readout in 72 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
433estimated
Sites
37
Countries
China, Hong Kong, Japan +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-18 | actual | When the study began enrolling |
| Primary completion | 2026-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Concomitant Procedures
- Atrial Fibrillation
- PFA
- LAAC
Intervention
- Device: FARAPULSE™ PFA system and WATCHMAN LAAC Delivery Systems
Primary outcomes
what the primary-completion date above is the date OFPeriprocedural or procedure-related Composite Serious Adverse Events will be assessed
measured 30 days post index procedure
Acute Treatment Success will be assessed
measured between index procedure and 30 days post index procedure
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed